- HK$1.59bn
- HK$1.12bn
- CNY247.15m
Annual balance sheet for Mega Genomics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 239 | 400 | 518 | 490 | 436 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 204 | 191 | 120 | 94.1 | 226 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 685 | 619 | 668 | 626 | 727 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 51.1 | 46.9 | 94 | 79.3 | 69.8 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 772 | 706 | 797 | 738 | 832 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 69.8 | 81.2 | 114 | 90.6 | 200 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 77.7 | 87.7 | 152 | 124 | 221 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 694 | 618 | 645 | 615 | 611 |
| Total Liabilities & Shareholders' Equity | 772 | 706 | 797 | 738 | 832 |
| Total Common Shares Outstanding |